French immuno-oncology biotech OSE eyes an EU IPO

The U.S. boom in biotech IPOs has largely failed to drift across the Atlantic and galvanize many floats in Europe, but France's OSE Pharma is looking to buck that trend in hopes of bankrolling late-stage studies for its immuno-oncology candidate. As Reuters reports, OSE has registered with French regulators to stage an IPO of undisclosed value, planning to support Texopi, an immunotherapy for lung cancer. The drug met its goals in a Phase II study on 135 patients with non-small cell lung cancer, the company said, and now OSE needs about $25 million to begin late-stage development, which it hopes to commence in the second half of 2015, according to Reuters. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.